age-related macular degeneration

Dopamine-Enhancing Therapies in Age-Related Macular Degeneration: Assessing Risk Reduction for Neovascular Conversion

By MedXY 06/25/2026

This study evaluates the association of dopamine-enhancing drugs, especially levodopa, with lowered 3-year risk of progression from non-neovascular to neovascular AMD, offering promising insight into dopaminergic pathways in AMD management.

news Ophthalmology Public Health

Large Multi-Center EMR Cohort Suggests NSAID Exposure Is Associated With Lower Future Risk of Age-Related Macular Degeneration

By MedXY 05/08/2026

In a large TriNetX retrospective cohort, prescribed NSAID use was associated with a lower subsequent risk of AMD, including both non-exudative and exudative disease, though residual confounding limits causal inference.

Diabetes & Endocrinology news Ophthalmology

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults

By MedXY 10/26/2025

A large retrospective cohort study reveals that GLP-1 receptor agonists significantly reduce the risk of developing nonexudative age-related macular degeneration in obese individuals without diabetes, with no effect on progression to exudative AMD.

Clinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Long-Term Metformin Use Linked to Reduced Risk of Age-Related Macular Degeneration in Diabetic Patients

By MedXY 08/17/2025

A large retrospective study found that diabetic patients using metformin for at least five consecutive years have a significantly lower risk of developing age-related macular degeneration, especially the dry type.